NASDAQ · Financial Statements

CAMP4 Therapeutics Corporation (CAMP) Financial Statements

$3.30 NASDAQ: CAMP Market Cap $207.09M

CAMP4 Therapeutics Corporation most recently reported annual revenue of $3.0M, a net loss of $80.0M. Revenue declined at an average annual rate of 60.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

CAMP4 Therapeutics Corporation: Revenue fell from $351.0M in 2016 to $3.0M in 2025, a change of -99.1% over 9 years; net profit was positive in 2 of 10 reported years; operating margin moved from 0.4% to -1488.3%, a shift of -1488.7 percentage points; the most recent year shows a net loss of $80.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$351.0M$366.0M$364.0M$366.0M$309.0M$296.0M$295.0M$0$1.0M$3.0M
Operating Expenses$350.0M$358.0M$344.0M$383.0M$315.0M$309.0M$320.0M$52.0M$54.0M$56.0M
Operating Profit$1.0M$8.0M$20.0M$-17.0M$-7.0M$-13.0M$-25.0M$-52.0M$-53.0M$-52.0M
Operating Margin0.4%2.2%5.4%-4.6%-2.2%-4.5%-8.4%-14822.6%-8142.3%-1488.3%
Other Income$2.0M$31.0M$13.0M$-42.0M$-2.0M$-2.0M$-7.0M$3.0M$1.0M$-28.0M
Interest$10.0M$10.0M$17.0M$20.0M$6.0M$5.0M$6.0M$0$0$0
Depreciation$23.0M$23.0M$20.0M$23.0M$22.0M$23.0M$1.0M$2.0M$2.0M$2.0M
Profit Before Tax$-7.0M$29.0M$24.0M$-58.0M$-21.0M$-30.0M$-31.0M$-49.0M$-52.0M$-80.0M
Tax$15.8M$37.2M$-5.6M$-35.1M$-2.7M$-3.6M$-3.7M$0$0$0
Net Profit$-7.0M$17.0M$18.0M$-79.0M$-56.0M$-28.0M$-32.0M$-49.0M$-52.0M$-80.0M
EPS$-0.20$0.46$0.52$-2.34$0.00$0.00$-0.90$-4.07$-2.66$-2.65
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$1.0M$1.0M$1.0M$1.0M$0$1.0M$2.0M
Operating Expenses$13.0M$13.0M$13.0M$13.0M$14.0M$15.0M$14.0M$15.0M$14.0M$13.0M$14.0M$15.0M
Operating Profit$-12.0M$-13.0M$-13.0M$-13.0M$-14.0M$-14.0M$-13.0M$-13.0M$-13.0M$-13.0M$-13.0M$-13.0M
Operating Margin-3525.1%0.0%0.0%0.0%0.0%-2152.4%-1526.8%-870.3%-1655.0%-3671.3%-1010.1%-752.1%
Interest$2.0M$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-12.0M$-13.0M$-12.0M$-13.0M$-13.0M$-13.0M$-12.0M$-13.0M$-15.0M$-40.0M$-18.0M$-34.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-12.0M$-13.0M$-12.0M$-13.0M$-13.0M$-13.0M$-12.0M$-13.0M$-15.0M$-40.0M$-18.0M$-34.0M
EPS$-0.11$-0.67$-1.03$-0.64$-0.69$-0.68$-0.64$-0.62$-0.55$-0.78$-0.32$-0.58

Over the 10 years reported for CAMP4 Therapeutics Corporation, borrowings decreased from $147.0M in 2016 to $2.0M in 2025, cash stood at $110.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.13 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$408.0M$473.0M$604.0M$496.0M$442.0M$402.0M$103.0M$55.0M$78.0M$118.0M
Current Assets$207.0M$276.0M$403.0M$238.0M$215.0M$194.0M$84.0M$40.0M$66.0M$114.0M
Cash$94.0M$133.0M$257.0M$107.0M$92.0M$91.0M$83.0M$38.0M$64.0M$110.0M
Inventory$29.0M$36.0M$32.0M$37.0M$32.0M$20.0M$0$0$0$0
Receivables$67.0M$72.0M$78.0M$72.0M$68.0M$59.0M$1.0M$0$0$0
Fixed Assets$21.0M$21.0M$27.0M$77.0M$62.0M$50.0M$17.0M$13.0M$10.0M$3.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$11.0M$32.0M$22.0M$0$24.0M$24.0M$0$0$0$1.0M
Other Assets$73.0M$73.0M$81.0M$106.0M$94.0M$94.0M$0$0$0$0
Total Liabilities$244.0M$274.0M$398.0M$358.0M$343.0M$322.0M$180.0M$179.0M$15.0M$70.0M
Current Liabilities$77.0M$96.0M$84.0M$121.0M$107.0M$95.0M$8.0M$8.0M$10.0M$16.0M
Borrowings$147.0M$154.0M$276.0M$234.0M$211.0M$209.0M$12.0M$12.0M$9.0M$2.0M
Other Liabilities$97.0M$120.0M$122.0M$123.0M$132.0M$113.0M$168.0M$167.0M$7.0M$68.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$164.0M$199.0M$206.0M$138.0M$99.0M$80.0M$-78.0M$-124.0M$63.0M$48.0M

For CAMP4 Therapeutics Corporation, operating cash flow was positive in 5 of 10 reported years; free cash flow in the latest year was negative at $30.0M; free cash flow was positive in 4 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$26.0M$67.0M$48.0M$12.0M$29.0M$-4.0M$-39.0M$-44.0M$-46.0M$-30.0M
Investing Cash Flow$28.0M$-50.0M$-26.0M$-69.0M$-25.0M$-21.0M$-8.0M$-1.0M$-1.0M$-1.0M
Financing Cash Flow$-51.0M$-2.0M$49.0M$-95.0M$-27.0M$-3.0M$100.0M$0$72.0M$15.0M
Net Cash Flow$-46.0M$39.0M$124.0M$-149.0M$-13.0M$-15.0M$83.0M$-45.0M$26.0M$46.0M
Free Cash Flow$18.0M$59.0M$37.0M$-10.0M$17.0M$-18.0M$-43.0M$-45.0M$-46.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-1.76
FCF Yield-13.50%
Quick Ratio4.70
Interest Coverage—
Return 1Y204.17%
Return 3Y—
Return 5Y—

CAMP4 Therapeutics Corporation (CAMP) financials — frequently asked questions

What is CAMP4 Therapeutics Corporation's annual revenue?

CAMP4 Therapeutics Corporation (CAMP) reported annual revenue of $3.0M in its most recent fiscal year.

What is CAMP4 Therapeutics Corporation's net profit?

CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $80.0M in its most recent fiscal year.

What is CAMP EV/EBITDA?

CAMP4 Therapeutics Corporation's enterprise value to EBITDA (EV/EBITDA) ratio is -1.76. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
CAMP Overview CAMP Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.